NIH to test Pfizer’s Paxlovid, other treatments as potential long Covid therapies

NIH to test Pfizer’s Paxlovid, other treatments as potential long Covid therapies


Paxlovid, Pfizer’s anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022.

Wolfgang Rattay | Reuters

The National Institutes of Health said Monday it launched mid-stage clinical trials to test at least four treatments, including Pfizer‘s antiviral Covid-19 pill Paxlovid, as potential therapies for long Covid. 

There is no proven treatment for the condition, which refers to symptoms that continue or develop in the weeks or months following an initial Covid infection. It affects an estimated 23 million Americans.

related investing news

This little-known pharma stock can rally 50%, Citi says

CNBC Pro

Health care providers typically try to treat the often debilitating symptoms associated with long Covid, such as chronic pain, memory loss and intense fatigue. But the lack of a specific long Covid treatment pushes some patients to seek unproven – and potentially dangerous – remedies for the condition. 

“We know that when patients are suffering, we can never move fast enough,” said acting NIH director Lawrence Tabak. “NIH is committed to a highly coordinated and scientifically rigorous approach to find treatments that will provide relief for the millions of people living with long COVID.”

NIH will test the safety and effectiveness of the treatments – which include both drugs and medical devices – in groups of 100 to 300 patients with long Covid symptoms. 

The first part of the phase two trial will test a longer dosing regimen of Paxlovid to see if it improves long Covid symptoms. 

Patients typically take Paxlovid within five days of developing Covid symptoms to reduce their risk of hospitalization or death, according to the Food and Drug Administration’s approval of the drug in May. To complete a full course of Paxlovid, patients must take three pills twice a day for five days. 

NIH said another part of the study will also test for brain fog and memory-related symptoms.

The agency will test medical treatments like a web-based brain training program called BrainHQ and a device that uses a small electric current to stimulate brain activity. 

NIH expects to launch additional clinical trials to test at least seven more treatments “in the coming months.” 



Source

Luxury credit card rivalry heats up as Amex, JPMorgan tease updates to their premier cards
Business

Luxury credit card rivalry heats up as Amex, JPMorgan tease updates to their premier cards

Anna Barclay | Getty Images The long-running rivalry between the country’s top premium credit cards is about to heat up again. JPMorgan Chase announced last week that a refresh of its Sapphire Reserve — the travel and dining rewards card that went viral when it arrived in 2016 — was imminent. In response, American Express […]

Read More
Starbucks moves to the next phase in its turnaround: Winning over employees
Business

Starbucks moves to the next phase in its turnaround: Winning over employees

Customers order at a Starbucks in Manhattan Beach, California, on July 19, 2024. Jakub Porzycki | Nurphoto | Getty Images As Starbucks aims to bring back customers and assuage investors with its turnaround strategy, it is also winning over its store managers with promises to add more seating inside cafes and promote internally. Since CEO […]

Read More
Boeing Dreamliner crash, military escalations darken mood at Paris Air Show
Business

Boeing Dreamliner crash, military escalations darken mood at Paris Air Show

The Boeing 787-9 civil jet airplane of Vietnam Airlines performs its flight display at the 51st Paris International Airshow in Le Bourget near Paris, France. (Photo by: aviation-images.com/Universal Images Group via Getty Images) aviation-images.com | Universal Images Group | Getty Images Kelly Ortberg’s first Paris Air Show as Boeing CEO was set to be relatively […]

Read More